This trial is evaluating whether perampanel will improve 6 primary outcomes and 12 secondary outcomes in patients with Aura. Measurement will happen over the course of Up to Week 52.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. Perampanel is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
There are many other conditions with similar symptomatology, and it is important to be aware of them in every patient presenting with a similar aura.
Aura is an ominous feeling of impending doom, pain, discomfort, and/or disorientation that may arise before a transient illness develops into more serious illness—a pre-epidemic condition. It often has no known underlying medical cause and is of particular concern to women. aura is a common phenomenon that can be diagnosed and treated and is unlikely to be life-threatening. For all persons, though, it is important to report those symptoms to healthcare providers for appropriate diagnosis and treatment. The word is from Greek: “aura”, meaning aura, “breath”.
The evidence for a causal relationship between the aura of a migraine and the migraine headache is circumstantial. The link is in the brain circuitry which is affected when there is a disturbance in neurons. The key features of the aura include visual field defects, visual imagery, and emotional changes. The role of the aura in triggering migraine with aura is complex and its significance as a diagnostic clue to identifying migraines as migraine depends on its interpretation by the observer.
The diagnosis can be made using a simple approach when the patients have some signs of aura that do not necessarily correspond to the name of this condition.
Although some studies suggest that a lifetime prevalence of aura of 6-12% might be a typical figure, the true extent of aura could be much higher. A systematic review of the literature suggests that aura may be as common as a co-morbidity in some populations; it should be considered not only as something which may be experienced, but also as something which may be diagnosed at various points in life.
The data herein have provided some general guidelines for the management of auras and will assist clinicians and research investigators as they attempt to determine treatments specific to the particular aura disorder.
The study results suggest that the treatment reduces the mean number of auras and the intensity of their overall pain. The treatment shows a significant statistical trend to reduce the intensity of aura and the corresponding scores in the group of women in comparison to other studies; and reduces the number of auras, but without achieving a statistical significance (P=0.101).
There is a need to establish the correct diagnosis of patients who present with auras. The differential diagnosis of aura should be explored as aura (psychosis). If a patient presents with auras, the following should be recorded: age, current symptoms, history of illness, and possible underlying causes such as head trauma.
When a seizure patient reports perampanel-like symptoms, hens, and especially the patient's spouse, should be aware that perampanel is associated with a high risk of serious seizures. Patients taking perampanel must be carefully monitored. If they have perampanel-like symptoms, they should be referred to a seizure service quickly.
The severity of the symptoms of typical aura is as great as or more intense than the symptoms of other types of aura and can affect the quality of life of patients and their families.
An elevated prevalence of familial auras and prodrome in a large family, the Liddle family with one third of the previous auras in the parents, was found and could be confirmed.
In this preliminary study, patients receiving Perampanel had a statistically significant improvement in general symptoms of depression, and marginally significant improvements in QoL as measured by the QALY, compared to placebo. Patients enrolled in this trial should therefore be advised to take Perampanel for a minimum of 16 weeks to maximize the potential for treatment change.